October 2020.
elong.Life has expanded its digital clinical trial matching program to include patients with multiple sclerosis (MS). The technology uses advanced artificial intelligence (AI) that processes a patient’s medical data and determines which trials in its global database are appropriate. The app typically returns results, which are prescreened by a clinical trial coordinator, in less than two days. More than 8,000 cancer patients have used the program so far.
Belong.Life is leading the charge in elevating patient engagement using conversational AI, big data and active patient communities.
Belong’s key solutions include the world’s largest social and professional networks for people living with cancer (Belong – Beating Cancer Together) and multiple sclerosis (BelongMS), and the BelongAI health-grade patient engagement and support platforms (including Dave – Cancer Mentor, Tara for clinical trial matching and more) which utilize AI to proactively support and empower patients throughout their healthcare journey. By enhancing patient education and providing 24/7 support, as well as access to relevant clinical trials, Belong is contributing to improved healthcare outcomes globally.
